Taxus chinensis Fruit Extract: Mechanistic Insights into TLR4-Mediated Neuroinflammation and Aging

Study Background and Research Question

Neuroinflammation and cellular senescence are central features of age-related neurological decline. Microglial activation, driven by inflammatory signaling cascades such as the TLR4/NF-κB/NLRP3 pathway, is a well-established contributor to this process. The fruit of Taxus chinensis (Pilg.) Rehder (TCF) has a rich ethnopharmacological history, being used for health-promoting effects in longevity villages in China. Despite anecdotal reports of its anti-aging benefits, the specific molecular mechanisms underlying these effects had not been systematically investigated.

To address this gap, the reference study (Chen Meimei et al., 2025) sought to elucidate whether TCF fruit extract (TCFE) could ameliorate aging-related behavioral and neuroinflammatory changes by inhibiting microglial activation via the TLR4/NF-κB/NLRP3 pathway. The research question was thus focused on defining the molecular and cellular impact of TCFE on neuroinflammation and aging markers, with a mechanistic emphasis on TLR4 signaling.

Key Innovation from the Reference Study

The central innovation of the study lies in its comprehensive demonstration that plant-derived bioactive compounds can selectively modulate TLR4-driven inflammatory signaling in the central nervous system. Through both in vivo (D-galactose-induced aging mice) and in vitro (LPS-stimulated BV2 microglia) models, the authors provided robust evidence that TCFE inhibits TLR4/NF-κB/NLRP3 pathway activity, thereby reducing neuroinflammation and aging phenotypes. Notably, the study integrates advanced molecular docking, UPLC-MS/MS compositional profiling, and comparative pharmacology to reveal that specific TCFE constituents—particularly procyanidin B2 and rutin—exhibit strong binding affinities for TLR4, supporting a direct mechanism for TLR4 inhibition. This establishes a new plant-based paradigm for targeted inhibition of neuroinflammatory pathways.

Methods and Experimental Design Insights

The experimental design was multifaceted, leveraging both animal and cell culture systems for mechanistic validation. Key methodological components included:

• Aging mouse model: Mice were subjected to chronic D-galactose administration to induce aging-like behavioral and biochemical phenotypes. TCFE was administered at three dosage levels, with a positive control group receiving rapamycin (2 mg/kg) and metformin (100 mg/kg).
• Behavioral and biochemical assessment: Researchers evaluated locomotor activity, cognitive performance, and measured serum markers of oxidative stress (MDA), antioxidant capacity (SOD, TAOC), and cytokines (IL-1β, IL-6, TNFα, IL-17, IL-10, IFNγ).
• Histological and molecular analyses: Hypothalamic β-galactosidase activity, p63 protein levels, and microglial activation status were assessed. Western blotting and qPCR quantified expression of components of the TLR4/NF-κB/NLRP3 axis.
• In vitro validation: BV2 microglia were stimulated with LPS to induce inflammatory responses, and the inhibitory effects of TCFE were compared to those of the classic TLR4 inhibitor C34 at 10 μM.
• Compositional analysis and docking: UPLC-MS/MS identified ten key bioactive compounds in TCFE. Molecular docking simulations were conducted to predict binding interactions with TLR4.

Protocol Parameters

• TCFE administration: Doses ranged from low to high, with optimal effects observed at higher concentrations in the aged mouse model.
• D-galactose induction: Chronic administration to establish a consistent aging phenotype before intervention.
• LPS stimulation (in vitro): Used to model acute microglial activation, with TCFE or C34 added to assess pathway-specific inhibition.
• Comparative inhibitor concentration: C34 validated at 10 μM for TLR4 signaling inhibition in cultured microglia, as reported in the product information.

Core Findings and Why They Matter

The study found that TCFE administration significantly improved behavioral deficits and reduced markers of oxidative stress and systemic inflammation in aged mice (reference study). Specifically:

• TCFE reduced MDA and pro-inflammatory cytokines (IL-1β, IL-6, TNFα, IL-17, IFNγ) while increasing antioxidant markers (SOD, TAOC) and anti-inflammatory cytokine IL-10.
• Microglial activation and expression of TLR4, NF-κB, and NLRP3 in the hypothalamus were significantly suppressed by TCFE, indicating effective inhibition of neuroinflammatory signaling.
• TCFE’s efficacy in reducing hypothalamic senescence and p63 levels was superior to the combination of rapamycin and metformin.
• In vitro, TCFE reduced TLR4, NF-κB, and IL-1β expression in LPS-stimulated BV2 microglia to an extent comparable to C34, supporting the hypothesis that its anti-inflammatory effects are largely driven by TLR4 pathway inhibition.
• Bioactive constituents of TCFE, including procyanidin B2 and rutin, demonstrated strong binding affinities to TLR4 in molecular docking analyses, suggesting a direct molecular interaction as the basis for pathway inhibition.

These findings are significant because they provide a mechanistic rationale for plant-derived inhibition of TLR4 in neuroinflammation and aging. The demonstration that TCFE can modulate microglial reactivity and inflammatory cascades through TLR4 suppression offers new avenues for translational research into neurodegenerative and age-related diseases.

Comparison with Existing Internal Articles

Several internal resources have previously summarized and interpreted the mechanistic impact of TCFE on neuroinflammation. For instance, Taxus chinensis Fruit Suppresses Neuroinflammation via TLR4 Inhibition and Taxus chinensis Fruit Extract Inhibits Neuroinflammation via TLR4 Pathway both highlight that TCFE’s attenuation of neuroinflammatory and aging phenotypes occurs through selective TLR4 pathway modulation. These articles reinforce the translational significance of targeting TLR4-mediated microglial activation as a unifying mechanism underlying both neurodegeneration and systemic aging.

Additionally, internal discussion of synthetic TLR4 inhibitors such as C34 (see C34 TLR4 Inhibitor: Precision Control in Necrotizing Enterocolitis Research) provides a useful benchmark for evaluating the effectiveness of plant-based inhibitors. The reference study’s direct comparison of TCFE and C34 in vitro underscores the value of C34 as a positive control for pathway-specific inhibition of TLR4 in microglia and supports its use in inflammatory signaling research beyond the context of enterocyte and macrophage biology.

Limitations and Transferability

While the study’s findings are robust within the context of aging-related neuroinflammation in mice, several limitations should be considered. First, the translation of these effects to human neurodegenerative diseases remains untested; human microglial responses and blood-brain barrier permeability may modulate efficacy. Second, although molecular docking supports direct interaction between TCFE constituents and TLR4, functional validation in human cells and tissues is required. Additionally, the comparative efficacy of TCFE versus synthetic small molecule TLR4 inhibitors outside of the central nervous system is not established, and off-target effects cannot be fully excluded. Finally, long-term safety of high-dose TCFE administration has not been assessed.

Research Support Resources

For researchers interested in recapitulating or extending these findings in inflammatory signaling research, the selective TLR4 inhibitor C34 (CAS 40592-88-9) TLR4 Inhibitor (SKU B4925) is available from APExBIO. C34 is a well-characterized small molecule that enables precise inhibition of TLR4 signaling in macrophages and enterocytes, and has been validated at 10 μM in vitro and 1 mg/kg in vivo for modulation of TLR4-driven inflammatory pathways according to the product information. For optimal experimental results, C34 is supplied as a crystalline solid, soluble in DMSO, and should be used promptly after solution preparation. This reagent can serve as a valuable control or complementary tool in studies of TLR4-mediated inflammation and necrotizing enterocolitis research workflows.